Edward Samuel
Directeur Technique/Scientifique/R&D chez ACHILLES THERAPEUTICS PLC
Postes actifs de Edward Samuel
Sociétés | Poste | Début | Fin |
---|---|---|---|
ACHILLES THERAPEUTICS PLC | Directeur Technique/Scientifique/R&D | 01/02/2022 | - |
Historique de carrière de Edward Samuel
Anciens postes connus de Edward Samuel
Sociétés | Poste | Début | Fin |
---|---|---|---|
Cognate BioServices, Inc.
Cognate BioServices, Inc. BiotechnologyHealth Technology Cognate BioServices, Inc. engages in the provision of commercialization services to regenerative medicine, cellular immunotherapy, and cell therapy companies. It offers cGMP clinical and commercial manufacturing; process and assay development and optimization; logistics, supply chain, and manufacturing support services; and clinical, regulatory, and custom services. The company was founded in 2002 and is headquartered in Memphis, TN. | Corporate Officer/Principal | - | - |
ORCHARD THERAPEUTICS PLC | Corporate Officer/Principal | - | - |
Formation de Edward Samuel
University College London | Doctorate Degree |
King's College London | Graduate Degree |
Statistiques
Internationale
Royaume-Uni | 5 |
Etats-Unis | 2 |
Opérationnelle
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ACHILLES THERAPEUTICS PLC | Health Technology |
Entreprise privées | 2 |
---|---|
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
Cognate BioServices, Inc.
Cognate BioServices, Inc. BiotechnologyHealth Technology Cognate BioServices, Inc. engages in the provision of commercialization services to regenerative medicine, cellular immunotherapy, and cell therapy companies. It offers cGMP clinical and commercial manufacturing; process and assay development and optimization; logistics, supply chain, and manufacturing support services; and clinical, regulatory, and custom services. The company was founded in 2002 and is headquartered in Memphis, TN. | Health Technology |
- Bourse
- Insiders
- Edward Samuel
- Expérience